Bharat Biotech has announced its entry into the contract research development and manufacturing organization (CRDMO) sector by establishing a new subsidiary, Nucelion Therapeutics Pvt Ltd, which will specialize in cell and gene therapies. This strategic move aims to bolster the company”s role in advanced therapeutic solutions.
Located within a 30,000 square foot facility in Genome Valley, Nucelion Therapeutics is set to provide a wide array of development and manufacturing services. These services will cater to innovative treatments targeting conditions such as cancers, autoimmune diseases, and rare genetic disorders. The new subsidiary has already launched a Good Manufacturing Practice (GMP) facility capable of producing plasmids, viral and non-viral vectors, as well as cell therapies, including aseptic fill and finish.
In a statement, Dr Krishna Ella, the founder chairman of Bharat Biotech and a non-executive director at Nucelion Therapeutics, emphasized the pivotal role of biological innovations in the future of pharmaceuticals. He stated, “The future of pharmaceutical innovation will be biological; CGTs are a key vector. Our vision is to integrate advanced therapy platforms into India”s healthcare ecosystem, enabling equitable solutions for complex and rare diseases.”
Dr Raghu Malapaka, chief business officer at Nucelion Therapeutics, highlighted that the CRDMO will offer comprehensive services for the development and manufacturing of plasmid DNA, viral vectors, and both autologous and allogeneic cell therapies. “The future of pharmaceutical innovation will be biological, with new modalities expected to drive a large share of growth worldwide,” he noted. The company aims to transition cell therapies from niche applications to scalable platforms that can address a broader range of medical needs, including oncology, immunology, and regenerative medicine.
By adhering to international regulatory standards, including those set by the US FDA and the EMA in Europe, Nucelion Therapeutics is poised to support global life science innovators with high-quality and scalable solutions in advanced therapies.
